Friday, June 27, 2025 6/27/2025

Pediatric Oncology In Vivo Testing Program Coordinating Center

Award Number: U24CA263963
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/25/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Pediatric Oncology In Vivo Testing Program Coordinating Center - PROJECT SUMMARY The overarching goal of NCI's Pediatric In Vivo Testing Program (Ped-In Vivo-TP) is to improve outcomes of pediatric cancer patients and to satisfy the requirements of the Research to Accelerate Cures and Equity (RACE) for Children Act to assess the efficacy of targeted anti-cancer agents developed for adults in pediatric contexts. To coordinate the activities of the new Ped-In Vivo-TP initiative, we have assembled a team of investigators from The Jackson Laboratory (JAX) and Seven Bridges Genomics (SB) with unique combined expertise and experience with in vivo cancer models, scalable cloud-based data management and analysis systems, informatics resource development, and multi-site project coordination. Combining the complementary strengths of JAX and SB provides the ideal foundation for a coordinating center to maximize the short- and long-term impacts of the Pediatric In Vivo Testing Program for advancing the application of precision medicine in pediatric oncology. We will manage a comprehensive and cohesive testing program to advance precision medicine in pediatric oncology through effective public-private partnerships among pharmaceutical companies, regulatory agencies, funders, and research organizations. We will achieve this goal through the following aims: Aim 1: Establish and maintain the Pediatric In Vivo Testing Coordinating Center (PIVOT CC) to provide administrative and logistical support for diverse stakeholders in the Pediatric in Vivo Testing Program consortium. We will draw on our team's combined decades of experience with multi-site program management, cancer model development, standardized testing of in vivo cancer models, data management and analysis, and informatics resource development to ensure timely decision making, conformance to standard protocols, resource tracking, and effective communications within the Ped-In Vivo-TP. Aim 2: Provide data management, statistical, and bioinformatics support to ensure data security and integrity. We will leverage existing protocols and software systems at JAX and SB to identify relevant in vivo cancer models and to collect, analyze, and securely manage data generated from testing centers within the consortium. We will perform statistical and bioinformatic analyses on consortium data to reliably inform the evaluation of the efficacy of novel therapeutic agents in a pediatric oncology setting. We will develop a public- facing data portal for sharing of data and methods with the broader scientific community. Aim 3: Provide scientific coordination to maintain an efficient and effective preclinical testing pipeline. We will draw from the extensive experience of our team with in vivo pharmacology and coordination of similar consortia to manage and coordinate the testing of agents by the Ped-In Vivo-TP centers at all stages of the process, from the identification of relevant in vivo models to the generation of final technical reports and publication of results. We will develop, record, and track performance metrics for the consortium to inform the evaluation of the program's success and impact.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $882,044 )
2025	2025	JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	5	6/2/2025	NON-COMPETING CONTINUATION	$882,044
														Subtotal = $882,044

Issue Date FY: 2024 ( Subtotal = $882,044 )
2024	2024	JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	4	6/25/2024	NON-COMPETING CONTINUATION	$882,044
														Subtotal = $882,044

Issue Date FY: 2023 ( Subtotal = $847,161 )
2023	2023	JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	001	3	9/13/2023	NON-COMPETING CONTINUATION	$16,944
2023	2023	JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	3	6/13/2023	NON-COMPETING CONTINUATION	$830,217
														Subtotal = $847,161

Issue Date FY: 2022 ( Subtotal = $830,217 )
2022	2022	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	2	9/7/2022	NON-COMPETING CONTINUATION	$830,217
														Subtotal = $830,217

Issue Date FY: 2021 ( Subtotal = $847,161 )
2021	2021	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	1	8/24/2021	NEW	$847,161
2021	2021	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	001	1	8/25/2021	NEW	$0
														Subtotal = $847,161

Grand Total All Awards = $4,288,627

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pediatric Oncology In Vivo Testing Program Coordinating Center

Award Number: U24CA263963

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/25/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer